Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY: XBI )

85.97 -1.18 (-1.35%)
Official Closing Price Updated: 8:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SPDR Series Trust SPDR S&P Biotech ETF

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Again, Buy ‘Em
Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more. 
Via Talk Markets
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
This Biotech Looks Good With Increased M&A activity
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets
The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%. 
Via Talk Markets
The “Shake It Off” Stock Market (And Sentiment Results)
We may be close to a short term peak in yields – bottom in bonds 
Via Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
When Will The Stock Market Stop Falling?
Stocks have fallen dramatically just this past week, is a bottom near? 
Via Talk Markets
Stocks Tank On May 11 With No Bottom In Sight
Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today. 
Via Talk Markets
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
“Threading The Needle” Stock Market (And Sentiment Results)
Two weeks ago AAII sentiment survey dropped to a 30 year low at 15.8% bullish. Last week it ticked up modestly to 16.4%. 
Via Talk Markets
7 Monster Stock Market Predictions For The Week Of April 25
The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC... 
Via Talk Markets
The “magic Chart” Stock Market (And Sentiment Results)
We have now come to a point Where the market has priced in more rate hikes than are likely to occur. 
Via Talk Markets
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
Healthcare Stocks Lead the Way Up as the Market Fades
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
Via Talk Markets
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results
SBFM stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells. 
Via InvestorPlace
Good Entry Point for Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
CNBC's Final Call: Newmont, Biotech ETF And This Energy Stock
On CNBC's "The Final Call," Carter Worth recommended Newmont Corporation (NYSE: NEM). The stock has jumped almost 36% year to date. 
Via Benzinga
Acadia: Helping With Alzheimers And Parkinsons
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
Biotech Funds and ETFs Continue to Lag
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are... 
Via Talk Markets
How do Biotechnology Funds and ETFs Perform Over Five Years?
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV. 
Via Talk Markets
AskSlim Market Week - Friday, March 18
Technical and cycle analysis, and market commentary. 
Via Talk Markets
3 Market ETF Stocks to Buy This Week on Fed Jitters
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over. 
Via InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.